Clinical Trials
25 trialsNCT03258567 2026-06-05
Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT05389423 2026-06-01
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT03394365 2026-05-22
ALLELE
Pierre Fabre Medicament
Phase 3 Recruiting
NCT06908096 2026-05-18
Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT06682442 2026-05-01
Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma
University of California, San Francisco
Phase NA Recruiting
NCT06119256 2026-04-02
Clinical Study of EBV-TCR-T Cells for EBV Infection After Allogenic HSCT
Chinese PLA General Hospital
Phase 1 Recruiting
NCT07478952 2026-03-24
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age
ModernaTX, Inc.
Phase 1 Recruiting
NCT07368634 2026-01-28
Exploratory Study of EBV-TCR-T Cell Injection for EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transplantation
Chinese PLA General Hospital
Phase 1/2 Recruiting
NCT07294547 2025-12-19
Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study
National Taiwan University Hospital
Phase NA Recruiting
NCT02048332 2025-12-16
VSTs
Children's Hospital Medical Center, Cincinnati
Phase 1/2 Recruiting
NCT02532452 2025-12-16
Third Party Viral Specific T-cells (VSTs)
Children's Hospital Medical Center, Cincinnati
Phase 2 Recruiting
NCT04664179 2025-12-12
CILESTE
Baylor College of Medicine
Phase 1 Recruiting
NCT06789159 2025-10-20
A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)
Thomas Jefferson University
Phase 1 Recruiting
NCT06909110 2025-08-14
Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity
Stanford University
Phase 1/2 Recruiting
NCT03266653 2025-08-08
EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection
New York Medical College
Phase 2 Recruiting
NCT04013802 2025-08-08
TETRAVI
Baylor College of Medicine
Phase 1 Recruiting
NCT06926894 2025-07-31
R-MVST Cells for Treatment of Viral Infections in Children and Young Adults
Columbia University
Phase 1 Recruiting
NCT04832607 2025-07-18
TRACE
University Hospital Freiburg
Phase 3 Recruiting
NCT05592626 2025-07-09
START-001
Marengo Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06870435 2025-03-11
Comparison and Strategy Optimization of Plasma EBV DNA and P85-Ab with VCA/EBNA1-IgA for Screening Nasopharyngeal Carcinoma in High-risk Areas
Sun Yat-sen University
Phase NA Recruiting
NCT05183490 2024-12-30
R-MVST Cells for Treatment of Viral Infections
Columbia University
Phase 1 Recruiting
NCT04308278 2024-10-30
EBVAST
Labo'Life
Phase 4 Recruiting
NCT04989491 2024-08-19
REPLY
University Hospital, Strasbourg, France
Phase 4 Recruiting
NCT06224049 2024-03-12
GI-hNeoT-01
BGI, China
Phase EARLY_PHASE1 Recruiting
NCT06135922 2023-11-18
Clinical Study of EBV-TCR-T Cells for EBV-associated Hemophagocytic Lymphohistiocytosis or EBV Infection
Chinese PLA General Hospital
Phase 1 Recruiting